We develop immune therapies that support the treatment and prevention of infectious disease and cancer

We develop immune therapies that directly stimulate a powerful immune response in the liver

Our lead programme is targeting a cure for the 250 million patients infected with chronic hepatitis B

Hepatitis B virus infection

Despite the availability of preventative vaccines, 2 billion people worldwide have been infected with hepatitis B virus (HBV). Over 250 million of those infected progress to chronic HBV infection and become susceptible to life threatening liver disease.  Avalia’s therapy aims to provide a necessary cure for these individuals.

Read More
>

Pipeline

Avalia’s immune therapies are designed to target the liver and spleen to modulate a more potent and targeted immune response against certain viruses and cancers. This is achieved by activating a special family of immune cells called natural killer T cells.

Read More
>

News

Collaborations for a COVID-19 vaccine

Avalia Immunotherapies to play role in new alliance in search for a COVID-19 vaccine for New Zealand.

Read More
>

A more effective malaria vaccine

Traditional malaria vaccines typically work by looking for foreign bodies or antigens present on the surface of the pathogen. While these ‘antibody-producing’ vaccines can be incredibly potent and offer long-term immunity, they don’t work as well against malaria—protecting only around…

Read More
>

Worth a shot? The economics of the race for a vaccine

Avalia's CEO Dr Shivali Gulab shares insights into the economics of COVID-19 vaccine development efforts alongside Associate Professor Helen Petousis-Harris, one of the New Zealand’s leading vaccine efficacy and safety experts, based at the University of Auckland.

Read More
>

Initial funding opens doors for national COVID-19 vaccine strategy

New Zealand biotech Avalia Immunotherapies has been awarded bridging funding of $100,000 from the Ministry of Business, Innovation and Employment’s COVID-19 Innovation Acceleration Fund to start work on securing a COVID-19 vaccine for New Zealand, until a national vaccine strategy…

Read More
>

Dr Kronenberg, elected distinguished fellow by AAI

Avalia's newly appointed director, Dr Mitch Kronenberg, receives highest honour for his outstanding scientific contributions to the field of immunology

Read More
>